Semaglutide mimics the effects of the naturally occurring GLP-1 hormone in your body that your small intestine makes
Current treatments, other than insulin supplementation, are sometimes not sufficient to achieve control and may cause undesirable side effects, such as weight gain and hypoglycemia
The potential of semaglutide once-weekly in patients without type 2 diabetes with weight regain or insufficient weight loss after bariatric surgery-a retrospective analysis
Detailed imaging and diagnostic evaluation revealed that the patient had a partial annular pancreas, a rare congenital abnormality in which pancreatic tissue partially surrounds the duodenum
The semaglutide products approved for weight reduction are Wegovy injection and, since December 22, 2025, Wegovy tablets at 25 mg
Molecular mechanisms of neuroprotection: The interplay of Klotho, SIRT-1, Nrf2, and HO-1 in neurological health